{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:59:39Z","timestamp":1793127579959,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40123-025-01250-8","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T14:56:23Z","timestamp":1758898583000},"page":"2735-2752","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Rising Importance of Antiseptics in Ophthalmology: From Endophthalmitis Prevention to Treatment of Ocular Infections"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-2391","authenticated-orcid":false,"given":"Andrzej","family":"Grzybowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Au\u0161rin\u0117","family":"Bajori\u016bnait\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reda","family":"\u017demaitien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"1250_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2021.08.012","volume":"235","author":"SN Patel","year":"2022","unstructured":"Patel SN, Cai LZ, Mahmoudzadeh R, et\u00a0al. Endophthalmitis after intravitreal anti-vascular endothelial factor injections: outcomes of eyes managed without microbiologic cultures. Am J Ophthalmol. 2022;235:1\u20136.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.oret.2022.01.022","volume":"6","author":"F Baudin","year":"2022","unstructured":"Baudin F, Benzenine E, Mariet AS, Ben Ghezala I, Bron AM, Daien V, et\u00a0al. Epidemiology of acute endophthalmitis after intraocular procedures: a national database study. Ophthalmol Retina. 2022;6:442\u20139.","journal-title":"Ophthalmol Retina"},{"key":"1250_CR3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2020-000464","volume":"6","author":"T Rossi","year":"2021","unstructured":"Rossi T, Romano MR, Iannetta D, Romano V, Gualdi L, D\u2019Agostino I, et\u00a0al. Cataract surgery practice patterns worldwide: a survey. BMJ Open Ophthalmol. 2021;6:e000464.","journal-title":"BMJ Open Ophthalmol"},{"key":"1250_CR4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41433-021-01886-3","volume":"37","author":"AY Ong","year":"2021","unstructured":"Ong AY, Rigaudy A, Toufeeq S, Robins J, Shalchi Z, Bindra MS, et\u00a0al. Intravitreal injections as a leading cause of acute postoperative endophthalmitis\u2014A regional survey in England. Eye. 2021;37:163.","journal-title":"Eye"},{"key":"1250_CR5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/ICU.0000000000000850","volume":"33","author":"D Patel","year":"2022","unstructured":"Patel D, Patel SN, Chaudhary V, Garg SJ. Complications of intravitreal injections: 2022. Curr Opin Ophthalmol. 2022;33:137\u201346.","journal-title":"Curr Opin Ophthalmol"},{"key":"1250_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/1469-0691.12118","volume":"19","author":"ML Durand","year":"2013","unstructured":"Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013;19:227.","journal-title":"Clin Microbiol Infect"},{"key":"1250_CR7","doi-asserted-by":"crossref","first-page":"e215","DOI":"10.1111\/aos.15732","volume":"102","author":"M Ferrara","year":"2024","unstructured":"Ferrara M, Gatti F, Lockington D, Iaria A, Kaye S, Virgili G, et\u00a0al. Antimicrobials and antiseptics: lowering effect on ocular surface bacterial flora \u2013 A systematic review. Acta Ophthalmol. 2024;102:e215\u201328.","journal-title":"Acta Ophthalmol"},{"key":"1250_CR8","first-page":"5186","volume":"64","author":"CM Sanfilippo","year":"2023","unstructured":"Sanfilippo CM, DeCory H, Asbell PA. Antibiotic resistance among ocular pathogens \u2013 An update from the 2022 ARMOR study. Invest Ophthalmol Vis Sci. 2023;64:5186\u20135186.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1250_CR9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s40123-023-00661-9","volume":"12","author":"A Borgia","year":"2023","unstructured":"Borgia A, Mazzuca D, Della Corte M, Gratteri N, Fossati G, Raimondi R, et\u00a0al. Prophylaxis of ocular infection in the setting of intraocular surgery: implications for clinical practice and risk management. Ophthalmol Ther. 2023;12:721\u201334.","journal-title":"Ophthalmol Ther"},{"key":"1250_CR10","unstructured":"Chlorhexidine facts: mechanism of action. https:\/\/www.chlorhexidinefacts.com\/mechanism-of-action.html. Accessed 22 Feb 2025"},{"key":"1250_CR11","first-page":"1321","volume":"19","author":"TM Karpi\u0144ski","year":"2015","unstructured":"Karpi\u0144ski TM, Szkaradkiewicz AK. Chlorhexidine\u2013pharmaco-biological activity and application. Eur Rev Med Pharmacol Sci. 2015;19:1321\u20136.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1250_CR12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jtos.2022.04.003","volume":"25","author":"AR Kaufman","year":"2022","unstructured":"Kaufman AR, Tu EY. Advances in the management of Acanthamoeba keratitis: a review of the literature and synthesized algorithmic approach. Ocul Surf. 2022;25:26\u201336.","journal-title":"Ocul Surf"},{"key":"1250_CR13","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/cod.14552","volume":"91","author":"SV Svendsen","year":"2024","unstructured":"Svendsen SV, Mortz CG, Mose KF. Contact allergy to topical ophthalmic medications: a retrospective single-centre study of three decades. Contact Dermatitis. 2024;91:119\u201325.","journal-title":"Contact Dermatitis"},{"key":"1250_CR14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.oret.2023.12.004","volume":"8","author":"NS Ton","year":"2024","unstructured":"Ton NS, Goncharov V, Zapata I, Adam MK. Endophthalmitis after anti-VEGF intravitreal injections with aqueous chlorhexidine versus povidone-iodine as ocular antiseptics. Ophthalmol Retina. 2024;8:521\u20136.","journal-title":"Ophthalmol Retina"},{"key":"1250_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/S40942-015-0010-Y","author":"R Merani","year":"2015","unstructured":"Merani R, Hunyor AP. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. Int J Retina Vitreous. 2015. https:\/\/doi.org\/10.1186\/S40942-015-0010-Y.","journal-title":"Int J Retina Vitreous"},{"key":"1250_CR16","doi-asserted-by":"crossref","first-page":"e808","DOI":"10.1111\/aos.12981","volume":"94","author":"CL Oakley","year":"2016","unstructured":"Oakley CL, Vote BJ. Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis. Acta Ophthalmol. 2016;94:e808\u20139.","journal-title":"Acta Ophthalmol"},{"key":"1250_CR17","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.survophthal.2025.01.013","volume":"70","author":"C Zhang","year":"2025","unstructured":"Zhang C, Lai D, Zhu D, Palka C, Reynolds A, Yannuzzi N. Chlorhexidine for ocular antisepsis before intravitreal injection: a systematic review and meta-analysis. Surv Ophthalmol. 2025;70:676\u201384.","journal-title":"Surv Ophthalmol"},{"key":"1250_CR18","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12348-024-00404-2","volume":"14","author":"CSP Batista","year":"2024","unstructured":"Batista CSP, Loscos-Gim\u00e9nez I, G\u00e1mez M, Altaba R, de Miniac D, Mart\u00ed N, et\u00a0al. Comparing the in vitro efficacy of chlorhexidine and povidone-iodine in the prevention of post-surgical endophthalmitis. J Ophthalmic Inflamm Infect. 2024;14:20.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1250_CR19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jtos.2021.06.011","volume":"22","author":"JY Liu","year":"2021","unstructured":"Liu JY, Chu HS, Wei YH, et\u00a0al. Review, analysis, and education of antiseptic related ocular injury in the surgical settings: antiseptic related ocular injuries. Ocul Surf. 2021;22:60\u201371.","journal-title":"Ocul Surf"},{"key":"1250_CR20","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12886-018-0844-9","volume":"18","author":"NJ Gili","year":"2018","unstructured":"Gili NJ, Noren T, T\u00f6rnquist E, Crafoord S, B\u00e4ckman A. Preoperative preparation of eye with chlorhexidine solution significantly reduces bacterial load prior to 23-gauge vitrectomy in Swedish health care. BMC Ophthalmol. 2018;18:167.","journal-title":"BMC Ophthalmol"},{"key":"1250_CR21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajo.2024.01.007","volume":"261","author":"V Romano","year":"2024","unstructured":"Romano V, Ferrara M, Gatti F, et\u00a0al. Topical antiseptics in minimizing ocular surface bacterial load before ophthalmic surgery: a randomized controlled trial. Am J Ophthalmol. 2024;261:165\u201375.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.oret.2023.08.007","volume":"8","author":"AV Mishra","year":"2024","unstructured":"Mishra AV, Tong CM, Faes L, et\u00a0al. Comparison of endophthalmitis rates after alcohol-based chlorhexidine and povidone-iodine antisepsis for intravitreal injections. Ophthalmol Retina. 2024;8:18\u201324.","journal-title":"Ophthalmol Retina"},{"key":"1250_CR23","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcjo.2024.01.012","volume":"59","author":"KA Stephenson","year":"2024","unstructured":"Stephenson KA, Merkur A, Kirker A, Albiani D, Pakzad-Vaezi K. Rates of endophthalmitis before and after transition from povidone-iodine to aqueous chlorhexidine asepsis for intravitreal injection. Can J Ophthalmol. 2024;59:424\u20139.","journal-title":"Can J Ophthalmol"},{"issue":"2","key":"1250_CR24","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1177\/11206721221124684","volume":"33","author":"A Niro","year":"2022","unstructured":"Niro A, Pignatelli F, Fallico M, et\u00a0al. Polyhexamethylene biguanide hydrochloride (PHMB)-Properties and application of an antiseptic agent. A narrative review. Eur J Ophthalmol. 2022;33(2):655\u201366.","journal-title":"Eur J Ophthalmol"},{"key":"1250_CR25","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1111\/aos.12347","volume":"92","author":"T Ristau","year":"2014","unstructured":"Ristau T, Kirchhof B, Fauser S. Antisepsis with polyhexanide is effective against endophthalmitis after intravitreal injections. Acta Ophthalmol. 2014;92:e494\u20136.","journal-title":"Acta Ophthalmol"},{"key":"1250_CR26","volume":"15","author":"NV Patel","year":"2023","unstructured":"Patel NV, Mathur U, Sawant S, Acharya M, Gandhi A. Three consecutive cases of ocular polyhexamethylene biguanide (PHMB) toxicity due to compounding error. Cureus. 2023;15:e38540.","journal-title":"Cureus"},{"key":"1250_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/11206721241299470","author":"A Franch","year":"2024","unstructured":"Franch A, Knutsson KA, Pedrotti E, Fasolo A, Bertuzzi F, Birattari F, et\u00a0al. Treatment of Acanthamoeba keratitis with high dose PHMB (0.08%) monotherapy in clinical practice: a case series. Eur J Ophthalmol. 2024. https:\/\/doi.org\/10.1177\/11206721241299470.","journal-title":"Eur J Ophthalmol"},{"key":"1250_CR28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/bjophthalmol-2020-317848","volume":"106","author":"V Papa","year":"2022","unstructured":"Papa V, Van Der Meulen I, Rottey S, Sallet G, Overweel J, Asero N, et\u00a0al. Safety and tolerability of topical polyhexamethylene biguanide: a randomised clinical trial in healthy adult volunteers. Br J Ophthalmol. 2022;106:190\u20136.","journal-title":"Br J Ophthalmol"},{"key":"1250_CR29","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1038\/s41433-022-02380-0","volume":"37","author":"B Rebattu","year":"2023","unstructured":"Rebattu B, Baillif S, Ferrete T, Risso K, Rabot A, Babeau F, et\u00a0al. Corneal foreign bodies: are antiseptics and antibiotics equally effective? Eye. 2023;37:2664.","journal-title":"Eye"},{"key":"1250_CR30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18240\/ijo.2020.01.13","volume":"13","author":"MV Budzinskaya","year":"2020","unstructured":"Budzinskaya MV, Khalatyan AS, Strakhovskaya MG, Zhukhovitsky VG. Ocular flora in patients undergoing intravitreal injections: antibiotic resistance patterns and susceptibility to antiseptic picloxydine. Int J Ophthalmol. 2020;13:85.","journal-title":"Int J Ophthalmol"},{"key":"1250_CR31","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/iwj.14060","volume":"20","author":"L Liu","year":"2023","unstructured":"Liu L, Zeng L, Gao L, Zeng J, Lu J. Ozone therapy for skin diseases: cellular and molecular mechanisms. Int Wound J. 2023;20:2376\u201385.","journal-title":"Int Wound J"},{"key":"1250_CR32","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.8.4","author":"G Celenza","year":"2020","unstructured":"Celenza G, Iorio R, Cracchiolo S, Petricca S, Costagliola C, Cinque B, et\u00a0al. Antimycotic activity of ozonized oil in liposome eye drops against Candida spp. Transl Vis Sci Technol. 2020. https:\/\/doi.org\/10.1167\/tvst.9.8.4.","journal-title":"Transl Vis Sci Technol"},{"key":"1250_CR33","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3390\/molecules25020334","volume":"25","author":"E Ugazio","year":"2020","unstructured":"Ugazio E, Tullio V, Binello A, Tagliapietra S, Dosio F. Ozonated oils as antimicrobial systems in topical applications. Their characterization, current applications, and advances in improved delivery techniques. Molecules. 2020;25:334.","journal-title":"Molecules"},{"key":"1250_CR34","doi-asserted-by":"crossref","first-page":"347","DOI":"10.4236\/jbise.2019.127026","volume":"12","author":"A Cutarelli","year":"2019","unstructured":"Cutarelli A, Carlini G, Sarno F, et\u00a0al. The role of ozone carried by liposomes in the therapy of infectious and skin-regenerating ocular surface. J Biomed Sci Eng. 2019;12:347\u201353.","journal-title":"J Biomed Sci Eng"},{"key":"1250_CR35","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.2147\/OPTH.S360929","volume":"16","author":"JJ P\u00e9rez-Santonja","year":"2022","unstructured":"P\u00e9rez-Santonja JJ, G\u00fcell JL, Gris O, Dorrego XMV, Pellicer E, Ben\u00edtez-Del-castillo JM. Liposomal ozonated oil in ocular infections: a review of preclinical and clinical studies, focusing on its antiseptic and regenerative properties. Clin Ophthalmol. 2022;16:1953.","journal-title":"Clin Ophthalmol"},{"key":"1250_CR36","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1007\/s40123-024-01006-w","volume":"13","author":"MO Grassi","year":"2024","unstructured":"Grassi MO, Boscia G, Alessio G, Zerbinati M, Petrara G, Puzo P, et\u00a0al. Liposomal ozonated oil ensures a further reduction in the microbial load before intravitreal injection: the \u201cOPERA\u201d study. Ophthalmol Ther. 2024;13:2771\u201388.","journal-title":"Ophthalmol Ther"},{"key":"1250_CR37","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1097\/j.jcrs.0000000000000672","volume":"47","author":"L Spadea","year":"2021","unstructured":"Spadea L, Zanotto E, Cavallo R, Campagna G, Giannico MI, Costagliola C. Effectiveness of liposomal ozonized oil in reducing ocular microbial flora in patients undergoing cataract surgery. J Cataract Refract Surg. 2021;47:1548\u201355.","journal-title":"J Cataract Refract Surg"},{"key":"1250_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS241814078","author":"V Gentili","year":"2023","unstructured":"Gentili V, Strazzabosco G, Salgari N, et\u00a0al. Ozonated oil in liposome eyedrops reduces the formation of biofilm, selection of antibiotic-resistant bacteria, and adhesion of bacteria to human corneal cells. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/IJMS241814078.","journal-title":"Int J Mol Sci"},{"key":"1250_CR39","first-page":"8631038","volume":"2022","author":"Z Li","year":"2022","unstructured":"Li Z, Wang H, Liang M, Li Z, Li Y, Zhou X, et\u00a0al. Hypochlorous acid can be the novel option for the meibomian gland dysfunction dry eye through ultrasonic atomization. Dis Markers. 2022;2022:8631038.","journal-title":"Dis Markers"},{"key":"1250_CR40","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1038\/s41598-019-38968-y","volume":"9","author":"MM Kiamco","year":"2019","unstructured":"Kiamco MM, Zmuda HM, Mohamed A, Call DR, Raval YS, Patel R, et\u00a0al. Hypochlorous-acid-generating electrochemical scaffold for treatment of wound biofilms. Sci Rep. 2019;9:2683.","journal-title":"Sci Rep"},{"key":"1250_CR41","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1097\/ICL.0000000000000415","volume":"44","author":"W Ngo","year":"2018","unstructured":"Ngo W, Jones L, Bitton E. Short-term comfort responses associated with the use of eyelid cleansing products to manage Demodex folliculorum. Eye Contact Lens. 2018;44:S87\u201392.","journal-title":"Eye Contact Lens"},{"key":"1250_CR42","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.2147\/OPTH.S328696","volume":"15","author":"R Kowalski","year":"2021","unstructured":"Kowalski R, Kamyar R, Rhee M, Mammen A, Dhaliwal D, Romanowski EG, et\u00a0al. The antibacterial comparison of 5% and 2.5% povidone iodine to 0.01% hypochlorous acid using corneoscleral tissue as a solid-phase medium. Clin Ophthalmol. 2021;15:3697.","journal-title":"Clin Ophthalmol"},{"key":"1250_CR43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1874364101913010029","volume":"13","author":"P Kanclerz","year":"2019","unstructured":"Kanclerz P, Grzybowski A, Olszewski B. Low efficacy of hypochlorous acid solution compared to povidone-iodine in cataract surgery antisepsis. Open Ophthalmol J. 2019;13:29\u201333.","journal-title":"Open Ophthalmol J"},{"key":"1250_CR44","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2022-3-10","volume":"11","author":"C Bertone","year":"2022","unstructured":"Bertone C, Mollicone A, Russo S, Sasso P, Fasciani R, Riccardi C, et\u00a0al. The role of hypochlorous acid in the management of eye infections: a case series. Drugs Context. 2022;11:2022\u20133\u201310.","journal-title":"Drugs Context"},{"key":"1250_CR45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/24741264211013622","volume":"6","author":"TW Hejkal","year":"2021","unstructured":"Hejkal TW, Maloley LA, Kaddoura L. Hypochlorous acid 0.01% vs povidone-iodine 5% for ocular antisepsis. J Vitreoretin Dis. 2021;6:132\u20137.","journal-title":"J Vitreoretin Dis"},{"key":"1250_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/S12886-017-0612-2","author":"M Teweldemedhin","year":"2017","unstructured":"Teweldemedhin M, Gebreyesus H, Atsbaha AH, Asgedom SW, Saravanan M. Bacterial profile of ocular infections: a systematic review. BMC Ophthalmol. 2017. https:\/\/doi.org\/10.1186\/S12886-017-0612-2.","journal-title":"BMC Ophthalmol"},{"key":"1250_CR47","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0161-6420(01)00899-5","volume":"109","author":"TA Ciulla","year":"2002","unstructured":"Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery: an evidence-based update. Ophthalmology. 2002;109:13\u201324.","journal-title":"Ophthalmology"},{"key":"1250_CR48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcrs.2014.04.040","volume":"41","author":"MM Nentwich","year":"2015","unstructured":"Nentwich MM, Ta CN, Kreutzer TC, Li B, Schwarzbach F, Yactayo-Miranda YM, et\u00a0al. Incidence of postoperative endophthalmitis from 1990 to 2009 using povidone-iodine but no intracameral antibiotics at a single academic institution. J Cataract Refract Surg. 2015;41:58\u201366.","journal-title":"J Cataract Refract Surg"},{"key":"1250_CR49","unstructured":"Barry P, Cordov\u00e9s L, Gardner S. ESCRS guidelines for prevention and treatment of endophthalmitis following cataract surgery: data, dilemmas and conclusions. Eur. Soc. Cataract Refract. Surg. 2013:1\u201344."},{"key":"1250_CR50","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.survophthal.2018.05.002","volume":"63","author":"JC Koerner","year":"2018","unstructured":"Koerner JC, George MJ, Meyer DR, Rosco MG, Habib MM. Povidone-iodine concentration and dosing in cataract surgery. Surv Ophthalmol. 2018;63:862\u20138.","journal-title":"Surv Ophthalmol"},{"key":"1250_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJO.2010.07.002","author":"H Shimada","year":"2011","unstructured":"Shimada H, Arai S, Nakashizuka H, Hattori T, Yuzawa M. Reduction of anterior chamber contamination rate after cataract surgery by intraoperative surface irrigation with 0.25% povidone-iodine. Am J Ophthalmol. 2011. https:\/\/doi.org\/10.1016\/J.AJO.2010.07.002.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2013.08.037","volume":"121","author":"P Storey","year":"2014","unstructured":"Storey P, Dollin M, Pitcher J, Reddy S, Vojtko J, Vander J, et\u00a0al. The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection. Ophthalmology. 2014;121:283\u20139.","journal-title":"Ophthalmology"},{"key":"1250_CR53","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3390\/jcm10102198","volume":"10","author":"R Musumeci","year":"2021","unstructured":"Musumeci R, Troiano P, Martinelli M, et\u00a0al. Effectiveness of 0.66% povidone-iodine eye drops on ocular surface flora before cataract surgery: a nationwide microbiological study. J Clin Med. 2021;10:2198.","journal-title":"J Clin Med"},{"key":"1250_CR54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000314699","volume":"23","author":"NO H\u00fcbner","year":"2010","unstructured":"H\u00fcbner NO, Siebert J, Kramer A. Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds. Skin Pharmacol Physiol. 2010;23:244\u201358.","journal-title":"Skin Pharmacol Physiol"},{"key":"1250_CR55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106146","volume":"56","author":"N Malanovic","year":"2020","unstructured":"Malanovic N, \u00d6n A, Pabst G, Zellner A, Lohner K. Octenidine: novel insights into the detailed killing mechanism of Gram-negative bacteria at a cellular and molecular level. Int J Antimicrob Agents. 2020;56:106146.","journal-title":"Int J Antimicrob Agents"},{"key":"1250_CR56","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.12968\/jowc.2016.25.Sup3.S1","volume":"25","author":"O Assadian","year":"2016","unstructured":"Assadian O, H\u00e4mmerle G, Lahnsteiner E, et\u00a0al. Facilitating wound bed preparation: properties and clinical efficacy of octenidine and octenidine-based products in modern wound management. J Wound Care. 2016;25:S1\u201327.","journal-title":"J Wound Care"},{"key":"1250_CR57","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/jop.2022.0122","volume":"39","author":"S Nair","year":"2023","unstructured":"Nair S, Zhu A, Jaffry M, Choudhry H, Dastjerdi MH. Povidone-iodine adverse effects and alternatives for ocular procedures. J Ocul Pharmacol Ther. 2023;39:207\u201314.","journal-title":"J Ocul Pharmacol Ther"},{"key":"1250_CR58","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1167\/tvst.8.5.17","volume":"8","author":"W Heaselgrave","year":"2019","unstructured":"Heaselgrave W, Hamad A, Coles S, Hau S. In vitro evaluation of the inhibitory effect of topical ophthalmic agents on Acanthamoeba viability. Transl Vis Sci Technol. 2019;8:17.","journal-title":"Transl Vis Sci Technol"},{"key":"1250_CR59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/iwj.12837","volume":"15","author":"J Matiasek","year":"2017","unstructured":"Matiasek J, Kienzl P, Otti GR, Turk BR, Djedovic G, Rieger UM. Aseptic surgical preparation for upper eyelid blepharoplasty via full-face octenidine antiseptic without antibiotic medication shows effective prophylaxis against post-surgical wound infection. Int Wound J. 2017;15:84.","journal-title":"Int Wound J"},{"key":"1250_CR60","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jcrs.2017.01.007","volume":"43","author":"MR Silas","year":"2017","unstructured":"Silas MR, Schroeder RM, Thomson RB, Myers WG. Optimizing the antisepsis protocol: effectiveness of 3 povidone\u2013iodine 1.0% applications versus a single application of povidone\u2013iodine 5.0%. J Cataract Refract Surg. 2017;43:400\u20134.","journal-title":"J Cataract Refract Surg"},{"key":"1250_CR61","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ophtha.2023.09.031","volume":"131","author":"JKG Dart","year":"2024","unstructured":"Dart JKG, Papa V, Rama P, et\u00a0al. The orphan drug for Acanthamoeba keratitis (ODAK) trial: PHMB 0.08% (polihexanide) and placebo versus PHMB 0.02% and propamidine 0.1%. Ophthalmology. 2024;131:277\u201387.","journal-title":"Ophthalmology"},{"key":"1250_CR62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajo.2021.05.018","volume":"231","author":"T Than","year":"2021","unstructured":"Than T, Morettin CE, Harthan JS, et\u00a0al. Efficacy of a single administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis. Am J Ophthalmol. 2021;231:28.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR63","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2018.05.012","volume":"194","author":"JS Pepose","year":"2018","unstructured":"Pepose JS, Ahuja A, Liu W, Narvekar A, Haque R. Randomized, controlled, phase 2 trial of povidone-iodine\/dexamethasone ophthalmic suspension for treatment of adenoviral conjunctivitis. Am J Ophthalmol. 2018;194:7\u201315.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR64","doi-asserted-by":"crossref","first-page":"e686","DOI":"10.1111\/aos.13416","volume":"95","author":"N Kovalyuk","year":"2017","unstructured":"Kovalyuk N, Kaiserman I, Mimouni M, Cohen O, Levartovsky S, Sherbany H, et\u00a0al. Treatment of adenoviral keratoconjunctivitis with a combination of povidone-iodine 1.0% and dexamethasone 0.1% drops: a clinical prospective controlled randomized study. Acta Ophthalmol. 2017;95:e686\u201392.","journal-title":"Acta Ophthalmol"},{"key":"1250_CR65","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ajo.2016.10.004","volume":"176","author":"SJ Isenberg","year":"2017","unstructured":"Isenberg SJ, Apt L, Valenton M, et\u00a0al. Prospective, randomized clinical trial of povidone-iodine 1.25% solution versus topical antibiotics for treatment of bacterial keratitis. Am J Ophthalmol. 2017;176:244\u201353.","journal-title":"Am J Ophthalmol"},{"key":"1250_CR66","doi-asserted-by":"crossref","first-page":"e928748","DOI":"10.12659\/AJCR.928748","volume":"22","author":"P Bordin","year":"2021","unstructured":"Bordin P. Low-concentration (0.66%) povidone iodine treatment of a corneal ulcer in a rheumatoid arthritis patient. Am J Case Rep. 2021;22:e928748\u201351.","journal-title":"Am J Case Rep"},{"key":"1250_CR67","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000524539","volume":"13","author":"S Castelnuovo","year":"2022","unstructured":"Castelnuovo S. Povidone iodine 0.66% to fight Pseudomonas aeruginosa in contact lens wearer: a case report. Case Rep Ophthalmol. 2022;13:398.","journal-title":"Case Rep Ophthalmol"},{"key":"1250_CR68","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/ICO.0000000000003390","volume":"43","author":"B Ramatchandirane","year":"2024","unstructured":"Ramatchandirane B, Chandrika YM, Najeeb S. Successful management of fungal keratitis caused by multidrug-resistant Cladosporium species using povidone-iodine. Cornea. 2024;43:125\u20138.","journal-title":"Cornea"},{"key":"1250_CR69","first-page":"280","volume":"56","author":"PS Adamson","year":"2015","unstructured":"Adamson PS, Roos H, von Holdt J. Treatment of bacterial and viral conjunctivitis with topical ultrapure stable hypochlorous acid (HOCl): a clinical evaluation and treatment response in 79 cases. Invest Ophthalmol Vis Sci. 2015;56:280\u2013280.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1250_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPHTH-2022-001209","author":"R Mencucci","year":"2023","unstructured":"Mencucci R, Morelli A, Favuzza E, Galano A, Roszkowska AM, Cennamo M. Hypochlorous acid hygiene solution in patients affected by blepharitis: a prospective randomised study. BMJ Open Ophthalmol. 2023. https:\/\/doi.org\/10.1136\/BMJOPHTH-2022-001209.","journal-title":"BMJ Open Ophthalmol"},{"key":"1250_CR71","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1177\/11206721231207116","volume":"34","author":"JM Ben\u00edtez-Del-Castillo","year":"2024","unstructured":"Ben\u00edtez-Del-Castillo JM. Liposomal ozonated oil effectiveness in the signs and symptoms of blepharitis in usual clinical practice. Eur J Ophthalmol. 2024;34:678\u201382.","journal-title":"Eur J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01250-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01250-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:42:19Z","timestamp":1760715739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01250-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1250"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01250-8","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Andrzej Grzybowski is an Editorial Board member of\n                      Ophthalmology and Therapy\n                      . Andrzej Grzybowski was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Au\u0161rin\u0117 Bajori\u016bnait\u0117 and Prof. Reda \u017demaitien\u0117 have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}